MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-11-2026
Evofem Biosciences EBITDA 2011-2026 | EVFM
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Evofem Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.39 M | -7.65 M | -17.4 M | -83.1 M | -166 M | -103 M | -52.5 M | -77.4 M | -10 M | -12 M | -42 M | -9.57 M | -14.4 M | -5.62 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.39 M | -166 M | -42.7 M |
Quarterly EBITDA Evofem Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.03 M | -1.14 M | 333 K | - | -2.14 M | - | -2.83 M | - | -3.05 M | -7.14 M | -3.33 M | - | -18 M | -23.9 M | -28.7 M | - | -42.6 M | -40.7 M | -44.7 M | - | -26 M | -22.2 M | -19.2 M | - | -14.1 M | -11.8 M | -13.6 M | - | -18.2 M | -23.1 M | -20.9 M | - | -8.89 M | -6.24 M | -4.86 M | - | -1.82 M | -2.48 M | -5.76 M | - | -16.9 M | -9.18 M | -6.63 M | - | -1.85 M | -1.97 M | -2.48 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 M | -44.7 M | -13 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
1.19 M | $ 0.9 | 0.78 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
232 M | $ 22.6 | 1.35 % | $ 3.75 B | USA |
 |
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.75 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.3 M | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
-26.7 M | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-41.4 M | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - |  Russia |
 |
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 6.78 | -1.02 % | $ 194 M | USA |
 |
ChromaDex Corporation
CDXC
|
16.9 M | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 2.34 | -1.48 % | $ 150 M | USA |
 |
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-29.5 M | - | 17.91 % | $ 11.1 M | USA |
 |
Genmab A/S
GMAB
|
6.57 B | $ 26.37 | -1.01 % | $ 16.5 B |  Danmark |
 |
BioNTech SE
BNTX
|
15.3 B | $ 101.6 | -0.45 % | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
-3.08 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-70.5 M | $ 4.1 | - | $ 438 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 23.28 | -0.6 % | $ 2.96 B | USA |
 |
Heron Therapeutics
HRTX
|
-224 K | $ 1.23 | 3.39 % | $ 205 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.49 | 4.58 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
ImmuCell Corporation
ICCC
|
4.43 M | $ 8.27 | 0.24 % | $ 74.6 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 2.9 | -0.64 % | $ 4.77 M | Israel |
 |
Innate Pharma S.A.
IPHA
|
-47.8 M | $ 1.42 | 1.31 % | $ 235 M | France |
 |
BeiGene, Ltd.
BGNE
|
589 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Inventiva S.A.
IVA
|
-52.1 M | $ 5.05 | -1.66 % | $ 138 M | France |